



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 5

Complete if Known	
Application Number	10/823,432
Filing Date	04/13/2004
First Named Inventor	Scott Baron
Art Unit	
Examiner Name	
Attorney Docket Number	PC18327A

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature _____ **Date Considered** _____

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2 of 5

Complete if Known

Application Number	10/823,432
Filing Date	April 13, 2004
First Named Inventor	Scott Baron
Group Art Unit	
Examiner Name	
Attorney Docket Number	PC18327A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		McLean MJ et al "Gabapentin as add-on therapy in refractory partial epilepsy" Neurol. 1993;43:2292-2298
		Field et al "Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity" Br. J. Pharmacol. 2001; 132:1-4
		Mauri MC et al "Gabapentin and the prophylaxis of bipolar disorders in patients intolerant to lithium" Clin. Drug invest. 2001;21(3):169-174
		Takasaki I. et al "Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection" Pharmacol. Exp. Ther. 2001;296(2):270-275
		Bauer CA and Brozoski TJ "Assessing tinnitus and prospective tinnitus therapeutics using a psychophysical animal model" JARO 2001;2/1:54-64
		Mathew NT et al "Efficacy of gabapentin in migraine prophylaxis" Headache 2001;41:119-128
		Loprinzi CL et al "Pilot evaluation of gabapentin for treating hot flashes" Mayo Clin. Proc. 2002;77(11):1159-1163
		Brown JP and Gee NS "Cloning and deletion mutagenesis of the alpha2delta calcium channel subunit from porcine cerebral cortex" J. Biol. Chem. 1998;273:25458-25465
		Gong HC et al "Tissue-specific expression and gabapentin-binding properties of calcium channel alpha2delta subunit subtypes" J. Membrane Biol. 2001;184:35-43
		Brodbeck J et al "The ducky mutation in cacna2d2 results in altered purkinje cell morphology and is associated with the expression of a truncated alpha2delta-2 protein with abnormal function" J. Biol. Chem. 2002;277(10):7684-7693
		Brill J et al "Entla, a novel CACNA2D2 mouse mutant" Society for neuroscience, 2002, Abstract, Program No. 619.3

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

5

Complete if Known

Application Number	10/823,432
Filing Date	April 13, 2004
First Named Inventor	Scott Baron
Group Art Unit	
Examiner Name	

Attorney Docket Number

PC18327A

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Stefani A et al "The effects of gabapentin on different ligand-and voltage-gated currents in isolated cortical neurons" Epilepsy Research 2001;43(3):239-238	
		Ng GY et al "Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action" Mol. Pharmacol. 2001;59(1):144-152	
		Wang M et al "Structural requirement of the calcium-channel subunit alpha2delta for gabapentin binding" Bioche. J. 1999;342:313-320	
		Brown JP et al "Isolation of the [3H]gabapentin-binding protein/alpha2delta Ca2+ channel subunit from porcine brain: development of a radioligand binding assay for alpha2delta subunits using [3H]leucine" Anal. Biochem 1998;255(2):236-243	
		Steele PM et al "Using genetic mutations to study the neural basis of behavior" Cell 1998;95(7):879-882	
		Anantharaman V and Aravind L "Cache-a signaling domain common to animal Ca2+-channel subunits and a class of prokaryotic chemotaxis receptors" Trends Biochem. Sci. 2000;25(11):535-537	
		Hain HS et al "Rapid assessment of operant learning and memory in mice" Society for Neuro. Annual Meeting Abs. 336.12	
		Lotarski SM et al "Characterization of the anxiolytic-like activity and side effects of pregabalin in mice" Society for Neuro. Annual Meeting Abs. 396.8	
		Krall et al "Antiepileptic drug development: II. Anticonvulsant drug screening" Epilepsia 1978;19(4):409-428	
		Bork P and Rohde K "More von Willebrand factor typ A domains? Sequence similarities with malaria thrombospondin-related anonymous protein, dihydropyridine-sensitive calcium channel and inter-alpha-trypsin inhibitor" Biochem. J. 1991;279(3):908-910	
		Wattler, S. et al "Construction of gene targeting vectors from lambdaKOS genomic libraries" Bio Techniques 1999;26:1150-1160	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete If Known	
Sheet	4	of	5	Application Number	10/823,432
				Filing Date	April 13, 2004
				First Named Inventor	Scott Baron
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	PC18327A

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		ACCESSION: M76559; DEFINITION: Human neuronal DHP-sensitive, voltage-dependent, calcium channel alpha-2b subunit mRNA, complete cds.
		ACCESSION: U73483; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta subunit, alpha2a isoform mRNA, complete cds.
		ACCESSION: U73484; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta subunit, alpha2b isoform mRNA, complete cds.
		ACCESSION: U73485; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta subunit, alpha2c isoform mRNA, complete cds.
		ACCESSION: U73486; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta subunit, alpha2d isoform mRNA, complete cds.
		ACCESSION: U73487; DEFINITION: Mus musculus voltage-gated calcium channel alpha2/delta subunit, alpha2e isoform mRNA, complete cds.
		ACCESSION: M86621; DEFINITION: Rat dihydropyridine-sensitive L-type calcium channel alpha-2 subunit (CCHL2A) gene, complete cds.
		ACCESSION: AF077665; DEFINITION: Sus scrofa voltage-dependent calcium channel alpha-2 delta subunit precursor, mRNA, complete cds.
		ACCESSION: AJ251368; DEFINITION: Homo sapiens mRNA for calcium channel, alpha 2/delta subunit 2 (CACNA2D2 gene), splice variant alpha2delta-2b.
		ACCESSION: AJ251367; DEFINITION: Homo sapiens mRNA for calcium channel, alpha 2/delta subunit 2 (CACNA2D2 gene), splice variant alpha2delta-2a.
		ACCESSION: AB011130; DEFINITION: Homo sapiens mRNA for KIAA0558 protein, partial cds.

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

5

Complete if Known

Application Number	10/823,432
Filing Date	April 13, 2004
First Named Inventor	Scott Baron
Group Art Unit	
Examiner Name	

Attorney Docket Number

PC18327A

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ACCESSION: NM_006030; DEFINITION: Homo sapiens calcium channel, voltage-dependent, alpha 2/delta subunit 2 (CACNA2D2), mRNA.	
		ACCESSION: AF040709; DEFINITION: Homo sapiens putative tumor suppressor gene 26 protein alpha 2 delta calcium channel subunit mRNA, complete cds.	
		ACCESSION: AF042792; DEFINITION: Homo sapiens alpha 2 delta calcium channel subunit isoform I mRNA, complete cds.	
		ACCESSION: AF042793; DEFINITION: Homo sapiens alpha 2 delta calcium channel subunit isoform II mRNA, complete cds.	
		ACCESSION: AF247139; DEFINITION: Mus musculus voltage-dependent calcium channel alpha-2-delta-2 subunit (Cacna2d2) mRNA, complete cds.	
		ACCESSION: AF247141; DEFINITION: Mus musculus voltage-dependent calcium channel alpha-2-delta-2 mutant subunit 2 (Cacna2d2) mRNA, complete cds.	
		ACCESSION: AB093246; DEFINITION: Mus musculus mRNA for mKIAA0558 protein.	
		ACCESSION: AK044603; DEFINITION: Mus musculus adult retina cDNA, RIKEN full-length enriched library, clone:A930026F23 product:calcium channel, voltage-dependent, alpha 2/delta subunit 2, full insert sequence.	
		ACCESSION: AF486277; DEFINITION: Rattus norvegicus calcium channel alpha-2 delta-2 subunit mRNA, complete cds.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313